| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.088 | 0.1 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.078 | 0.1 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.1 |